N 0923

Known as: N-0923 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1992-2001
02419922001

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
N-0923 is a non-ergot, dopaminergic D(2) agonist designed to be transdermally available. It has anti-parkinsonian effects when… (More)
Is this relevant?
1999
1999
Nicotine, the soluble methyl ester of L-DOPA, and the D(2) agonist N-0923 were given alone and in combination im to five… (More)
Is this relevant?
1998
1998
N-0923, a novel aminotetralin dopamine D2 agonist, was shown to effectively reverse parkinsonian symptoms in nine dopa/agonist… (More)
Is this relevant?
1998
1998
The effects of the antiparkinsonian agent trihexyphenidyl, a selective M1 muscarinic cholinergic receptor antagonist, were… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1995
1995
The potencies for in vivo inhibition of substantia nigra pars compacta dopamine single cell firing were determined for… (More)
Is this relevant?
1994
1994
Certain aminotetralins are known to be potent dopamine D2 receptor agonists. N-0923, [-]2-(N-propyl-N-2-thienylethylamino)-5… (More)
Is this relevant?
1994
1994
The metabolism of the dopamine D2 agonist N-0923 was investigated by an in vitro isolated liver perfusion. Determining the… (More)
Is this relevant?
1993
1993
The noncompetitive N-methyl-D-aspartate antagonist (5R,10S)-(+)-5-methyl- 10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine… (More)
Is this relevant?
1993
1993
Using the hippocampal-slice preparation, we attempted to model operant conditioning in vitro by reinforcing pyramidal cell… (More)
Is this relevant?
1992
1992
The absorption of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxy-tetralin hydrochloride (1; N-0923… (More)
Is this relevant?